Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
New developments of aminobisphosphonates: the double face of Janus Santini D; Galluzzo S; Vincenzi B; Schiavon G; Fratto E; Pantano F; Tonini GAnn Oncol 2007[Jun]; 18 Suppl 6 (ä): vi164-7BACKGROUND: Bisphosphonate (BP) therapy has become a standard of therapy for patients with malignant bone disease. In vivo preclinical and preliminary clinical data indicate that BPs may prevent cancer treatment-induced bone loss and the onset of malignant bone disease in patients with early-stage cancer. DESIGN: This review will describe the preclinical evidences of action of BPs on osteoclasts and tumor cells. In addition, the effects of principal BPs on skeletal disease progression in patients with breast cancer, prostate cancer, non-small-cell lung cancer and other cancers will be reported. The preliminary clinical data from retrospective trials on the effect of zoledronic acid (ZA) on survival will be described and the ongoing adjuvant phase III trial will be analyzed. CONCLUSIONS: This review will describe the preliminary clinical evidences from prospective studies on the effect of ZA treatment on the prevention of bone metastasis.|Animals[MESH]|Antineoplastic Agents/*therapeutic use[MESH]|Bone Density Conservation Agents/*therapeutic use[MESH]|Bone Neoplasms/*drug therapy/secondary[MESH]|Bone Resorption/prevention & control[MESH]|Diphosphonates/*therapeutic use[MESH]|Humans[MESH]|Imidazoles/*therapeutic use[MESH]|Zoledronic Acid[MESH] |
